Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
OXNARD, Calif., May 18, 2017 -- CURE Pharmaceutical (OTCQB:CURR), (“CURE”), a leading disruptive drug delivery technology and pharmaceutical cannabinoid molecule development company, announced today publication by the Unites States Patent and Trademark Office (USPTO) of its Patent application entitled “Pharmaceutical Composition with Ionically Crosslinked Polymer Encapsulation of Active Ingredient.” This patent application, which has been assigned USPTO publication number US-2017-0100327 to CURE Pharmaceutical, covers the Company’s proprietary CureFilm™ drug delivery technology.
“This publication by the USPTO of our Crosslink patent is an important step in the application process, moving us closer to our goal of approval and issuance of this patent,” said Rob Davidson, CEO of CURE. “This is yet another milestone in the advances CURE continues to make in our technology platform, taking our product capabilities to even higher levels, allowing us to offer highly effective products that contain precisely controlled levels of an active or multiple actives in a stable, convenient and practical platform.”
The patent, which covers compositions and thin films containing an encapsulated pharmaceutical ingredient, as well as methods of manufacturing and using the same, allows for better stability and delivery into the lower GI system, increasing the potential for absorption into the blood without degradation of the active ingredient. It also allows for the combination of active pharmaceutical ingredients on one thin film without negative interaction.
CURE's intellectual property (IP) development strategy focuses on improving product integrity, efficiency and load capacity for all drug delivery technologies. CURE has protected these innovations using a blended strategy of patents, trade secrets and proprietary equipment design.
CURE has a broad and growing patent portfolio, with several patents issued and pending:
| PATENTS ISSUED | |||
| SLW File Number | Title | Application Number | Patent Number |
| 3768.003US2 | METHOD AND APPARATUS FOR MINIMIZING HEAT, MOISTURE, AND SHEAR DAMAGE TO MEDICANTS AND OTHER COMPOSITIONS DURING INCORPORATION OF SAME WITH EDIBLE | 11/836,758 | US 8,840, 919 B2 |
| 3768.007US1 | METHODS FOR MODULATING DISSOLUTION, BIOAVAILABILITY, BIOEQUIVALENCE, AND DRUG DELIVERY PROFILE ON THIN FILM DRUG DELIVERY SYSTEMS, CONTROLLED-RELEASE THIN FILM DRUG DELIVERY SYSTEMS, CONTROLLED RELEASE THIN FILM DOSAGE FORMATS, AND METHODS FOR THEIR MANUFACTURE AND USE | 11/371,167 | US 8,999,372 B2 |
| 3768.003US3 | METHOD AND APPARATUS FOR MINIMIZING HEAT, MOISTURE AND SHEAR DAMAGE TO MEDICANTS AND OTHER COMPOSITIONS DURING INCORPORATION OF SAME WITH EDIBLE FILMS | 14/490,959 | US 9,155,698 B2 |
| 3768.028MX1 | EDIBLE FILM FOR TRANSMUCOSAL DELIVERY OF NUTRITIONAL SUPPLEMENTS (MEXICO) | MX/A/2007/013708 | |
| 3768.006US1 | EDIBLE FILMS FOR ADMINISTRATION OF MEDICAMENTS TO ANIMALS, METHODS FOR THEIR MANUFACTURE AND METHODS FOR THEIR USE FOR THE TREATMENT OF ANIMALS | 10/921,770 | US 9,561,182 B2 |
| PATENTS PENDING | |||
| 3768.004US2 | METHOD AND APPARATUS FOR MINIMIZING HEAT, MOISTURE AND SHEAR DAMAGE TO MEDICANTS AND OTHER COMPOSITIONS DURING INCORPORATION OF SAME WITH EDIBLE FILMS | 12/251,349 | N/A |
| 3768.010CN1 | THIN FILM WITH HIGH LOAD OF ACTIVE INGREDIENT | PCT/US2014/037522 | N/A |
| 3768.010US1 | THIN FILM WITH HIGH LOAD OF ACTIVE INGREDIENT | 13/890,875 | N/A |
| 3768.011US1 | PHARMACEUTICAL COMPOSITION WITH SEQUESTRATION OF ACTIVE PHARMACEUTICAL INGREDIENT | 15/315,264 | N/A |
| 3768.011WO1 | PHARMACEUTICAL COMPOSITION WITH SEQUESTRATION OF ACTIVE PHARMACEUTICAL INGREDIENT | PCT/US2015/033274 | N/A |
| 3768.024US1 | THIN FILM WITH HIGH LOAD OF ACTIVE INGREDIENT | 14/069,239 | N/A |
About CURE Pharmaceutical
Headquartered in Oxnard, California, CURE Pharmaceutical (OTC:CURE) is a fully integrated specialty pharmaceutical/bioscience company that leverages disruptive proprietary drug delivery technologies for a broad range of molecules serving the biopharmaceutical, veterinarian, medical foods and pharmaceutical cannabis markets. CURE develops its patented and proprietary delivery system (CureFilm™), the most advanced oral thin film on the market today, from its industry leading full service cGMP manufacturing facility. The Company’s mission is to deliver proven drugs in a fast and efficient manner and to improve the quality of life.
Forward-looking statements
This press release contains forward-looking statements, which are subject to risks and uncertainties. All statements, other than statements of fact, including those statements with respect to the Company's business development, are forward-looking statements. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.
Contact: Andrew Hard CMW Media [email protected] 917.660.5418
